Programme
Time | Session | Location |
---|---|---|
08:30 - 09:00 | Registration | Foyer → |
09:00 - 09:45 | Welcome & Keynote Address → | Queensberry → |
09:50 - 10:30 | Free | Foyer → |
10:35 - 11:15 | Session 2 → | Mayfair → |
11:15 - 11:45 | Coffee | Foyer → |
11:45 - 12:25 | Free | Foyer → |
12:25 - 13:05 | Session 4 → | Mayfair → |
13:05 - 14:20 | Lunch → | Queensberry → |
14:20 - 15:00 | Free | Foyer → |
15:00 - 15:40 | Session 6 → | Mayfair → |
15:40 - 16:10 | Tea | Foyer → |
16:10 - 16:50 | Free | Foyer → |
16:50 - 17:30 | Session 8 → | Mayfair → |
17:30 | Drinks reception | Domino → |
Keynote and Delegates
- Keynote address
-
Investing in the 21st Century Brain
‘Investment’ in the brain can be viewed in two ways: personal development and professional profit. We all have a personal interest in the brain, since it is the basis of our unique minds. The wonderful thing about being a human being is that although we are born with a full complement of brain cells, it is the growth of connections between the cells that accounts for the growth of the brain after birth. These connections reflect the unique sequence, a life-story, of individual experiences and interactions with the outside world: a phenomenon known as ‘plasticity’ that leads to the personalisation of the physical brain, amounting to a ‘mind’. Given the unprecedented challenges posed by the digital world to thinking, emotions and well-being, we need to devise the best ways for optimising fulfilment of each individual’s potential, as well evaluating the best possible investments arising from digital technologies and AI. The other significant factor for the well being of the 21st Century brain, and indeed in the opportunity for high return investment, is the increase in prevalence of Alzheimer’s Disease. The global market for AD treatment will more than double in value from $4.9 billion in 2013, to reach an estimated $13.3 billion in 2023. However, the challenge is to devise a treatment that tackles not the consequence of neurodegeneration i.e., amyloid plaques, but the actual cause. We shall explore a disruptive approach based on the pivotal mechanism of degeneration, leading to a possible pre-symptomatic lateral flow test for Alzheimer’s as well as a first-in-class therapeutic with proven efficacy in a living animal model. The combination of a presymptomatic screen coupled with an drug treatment that halted cell loss, would amount to an effective ‘cure’. This would surely be a great investment, both on a personal as well as a professional level!
Baroness Susan Greenfield
CBE, FRCP (Hon)
Baroness Greenfield, Founder and CEO of Neuro-Bio Ltd is a neuroscientist, writer and broadcaster. She has published over 200 papers in peer-reviewed journals, based mainly at Oxford University but has held research fellowships at the College de France Paris, NYU Medical Center New York and Melbourne University. She holds 32 honorary degrees from UK and foreign universities, has received numerous honours including the Legion d’Honneur from the French Government, an Honorary Fellowship from the Royal College of Physicians, The American Academy of Achievement Golden Plate Award, and The Australian Medical Research Society Medal. She is also a Fellow of the Royal Society of Edinburgh.
- Session 2
-
Mayfair
Derek Beatty
Portfolio Manager
Julius BaerRobert Burdett
Head of Multi-Manager Solutions
Columbia Threadneedle Multi-ManagerAdam Carruthers
Collectives Analyst
Charles Stanley & CoWee-Tsen Lee
Head of Fund Research
Lockhart Capital ManagementDarren Morgan
Portfolio Director
Cazenove CapitalAmanda Sillars
Fund Manager, ESG Director: JIF Team
Jupiter Asset ManagementMatthew Stanesby
Managing Director
Close Brothers Asset Management
- Session 4
-
Mayfair
Ian Goodchild
Investment Director
Mattioli WoodsTom Jemmett
Head of Authorised Funds
LGT Wealth ManagementJohn Monaghan
Research Director
Square MileRichard Philbin
Chief Investment Officer (Solutions)
Hawksmoor Investment ManagementNathan Sweeney
Deputy CIO - Multi-Asset
Marlborough Investment ManagementDavid Thornton
Fund Manager
Premier Miton Investors
- Lunch
-
Queensberry
Tom Jemmett
Head of Authorised Funds
LGT Wealth ManagementMatthew Stanesby
Managing Director
Close Brothers Asset ManagementNathan Sweeney
Deputy CIO - Multi-Asset
Marlborough Investment Management
- Session 6
-
Mayfair
Tom Caddick
Managing Director
NedGroup InvestmentsDavid Jardine
Head of Portfolio Management
STANLIB Multi-ManagerRichard Larner
Head of Research
Brooks MacdonaldMark Preskett
Senior Portfolio Manager
MorningstarMark Richmond-Watson
Portfolio Manager
James Hambro & PartnersJulia Warrander
Group Director
Affinity Private Wealth
- Session 8
-
Mayfair
Mireille Bensimon
Investment Analyst
Legal & General Investment ManagementCristina Dondiuc
Research Analyst
Fidelity InternationalCameron Falconer
Head of Investment Oversight & Manager Research
Aviva InvestorsMark Shapley
CIO
Alder InvestmentRichard Swain
Head of Funds Research
Bentley ReidRichard Warne
Senior Portfolio Manager
Copia Capital
Downloads
Information
The Next Generation Forum was devised and organised by Infusion Events. We will be available throughout the event and we will be happy to help with any queries you may have. Please come and find us at the registration desk or phone us on one of the following mobile numbers:
Sally Doyle 07881 957350
Sarah Ford 07702 331487
Wi-Fi
Should you wish to catch up with the office during your breaks, we have arranged a complimentary and secure Wi-Fi connection:
SSID: NGF23*
Password: 23FGN2023
Drinks Reception
A reminder that the Drinks Reception will commence at 17.30 in Domino, which is also on this floor of the hotel. Please refer to the floorplan section or we will be happy to direct you. Dress code remains Business Attire.
Transport
We recommend the following reliable car service: